Drug Trial Radar · NCT00005002
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
688
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Agouron PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.
Conditions
- HIV Infections
Interventions
Lamivudine/ZidovudineDrug
HIV-1 ImmunogenBiological
Nelfinavir mesylateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Agouron Pharmaceuticals Inc
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.